{"id":"dapsone-gel-vehicle","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site erythema"},{"rate":null,"effect":"Application site dryness"},{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Oiliness/seborrhea"}]},"_chembl":{"chemblId":"CHEMBL1043","moleculeType":"Small molecule","molecularWeight":"248.31"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Dapsone works through dual mechanisms: it inhibits folate synthesis in bacteria and has potent anti-inflammatory effects by suppressing neutrophil function and reducing the production of inflammatory mediators. In topical gel formulation, it is used to treat acne and other inflammatory skin conditions by reducing bacterial colonization and neutrophil-mediated inflammation in the skin.","oneSentence":"Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties, reducing neutrophil migration and reactive oxygen species production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:34.788Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris (topical gel formulation)"}]},"trialDetails":[{"nctId":"NCT07244887","phase":"PHASE4","title":"Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgaris","status":"ENROLLING_BY_INVITATION","sponsor":"Oya Helin Dundar","startDate":"2025-06-17","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT02108483","phase":"PHASE1","title":"Phototoxicity Test of Dapsone Gel in Healthy Volunteers","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2014-04","conditions":"Healthy Volunteers","enrollment":33},{"nctId":"NCT02117739","phase":"PHASE1","title":"Photoallergy Potential of Dapsone Gel in Healthy Volunteers","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2014-04","conditions":"Healthy Volunteers","enrollment":58},{"nctId":"NCT01974323","phase":"PHASE3","title":"Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2013-11","conditions":"Acne Vulgaris","enrollment":2238},{"nctId":"NCT02117752","phase":"PHASE1","title":"Dermal Tolerability of Dapsone Gel in Healthy Volunteers","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2014-04","conditions":"Healthy Volunteers","enrollment":237},{"nctId":"NCT01974141","phase":"PHASE3","title":"A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2013-11","conditions":"Acne Vulgaris","enrollment":2102},{"nctId":"NCT03132194","phase":"PHASE1","title":"Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-08-08","conditions":"Acne Vulgaris","enrollment":1125},{"nctId":"NCT02929719","phase":"PHASE1","title":"Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2014-04","conditions":"Acne Vulgaris","enrollment":1134},{"nctId":"NCT02865005","phase":"PHASE3","title":"Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Seegpharm S.A.","startDate":"2016-02","conditions":"Acne Vulgaris","enrollment":2361},{"nctId":"NCT01870050","phase":"NA","title":"Dapsone Prurigo Study","status":"UNKNOWN","sponsor":"Cook County Health","startDate":"2013-09","conditions":"Lichen Simples Chronicus and Prurigo","enrollment":20},{"nctId":"NCT00243542","phase":"PHASE4","title":"Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-11","conditions":"Acne Vulgaris","enrollment":64},{"nctId":"NCT00343187","phase":"PHASE2","title":"A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash","status":"TERMINATED","sponsor":"Allergan","startDate":"2006-06","conditions":"Rash, Non-small-Cell Lung Cancer","enrollment":2},{"nctId":"NCT00249782","phase":"PHASE2","title":"A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-11","conditions":"Rosacea","enrollment":400},{"nctId":"NCT00151541","phase":"PHASE3","title":"A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-02","conditions":"Acne Vulgaris","enrollment":301}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"dapsone gel vehicle","genericName":"dapsone gel vehicle","companyName":"Almirall, S.A.","companyId":"almirall-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties, reducing neutrophil migration and reactive oxygen species production. Used for Acne vulgaris (topical gel formulation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}